Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-03-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于两子公司吸收合并的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the absorption merger of two subsidiaries of 普洛药业股份有限公司. It details the merger process, the companies involved, financial figures, and the impact of the merger. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is not a regulatory filing or certification. The document is a formal announcement of a corporate restructuring event (merger of subsidiaries) and does not fit into categories like M&A filings for external mergers or acquisitions but rather internal restructuring. The best fitting category is Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through merger of subsidiaries.
2015-03-13 Chinese
关于公司与华海药业合作的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a cooperation agreement and capital increase between the company and another pharmaceutical company. It details the transaction parties, the capital increase agreement, and the impact of the transaction. It explicitly states that the transaction does not constitute a related party transaction or a major asset restructuring and does not require shareholder approval. There are no financial statements or comprehensive financial reports included, only summary financial data to support the announcement. The document is relatively short (1844 characters) and serves as a formal disclosure of a capital/financing update related to a joint investment and capital increase. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2015-03-13 Chinese
关于收到中国证券监督管理委员会浙江证监局《关于对普洛药业股份有限公司采取出具警示函措施的决定》的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding a regulatory warning letter issued by the China Securities Regulatory Commission Zhejiang Bureau. It details findings of non-compliance and financial inaccuracies discovered during an inspection, and the company's response and commitment to rectify the issues. The document does not contain financial statements or detailed financial data itself, nor is it a full audit report or annual report. It is a regulatory announcement about legal and compliance matters related to the company. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2015-03-06 Chinese
2014年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a 2014年度业绩快报, which translates to '2014 Annual Performance Express Report' or 'Annual Earnings Quick Report'. It contains preliminary financial data for the year 2014, including revenue, profit, net income, earnings per share, and asset and equity figures. The document explicitly states that the financial data is preliminary and unaudited. It also includes explanations of operating performance and financial condition, with specific figures and percentage changes compared to the previous year. The document is relatively short (1528 characters) and provides substantive financial data and analysis for a full fiscal year, which aligns with the characteristics of an Annual Report or a similar comprehensive yearly financial report. However, since it is a preliminary earnings announcement (快报) and not a full audited annual report (10-K), it fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER). FY 2014
2015-02-13 Chinese
关于公司独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It discusses the resignation report, regulatory compliance about board composition, and plans to fill the vacancy. There is no financial data, no report or presentation attached, and no mention of voting results or other report types. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-01-14 Chinese
2014年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2014 annual performance forecast (业绩预告) for 普洛药业股份有限公司, covering the full fiscal year from January 1, 2014 to December 31, 2014. It provides estimated net profit and earnings per share figures, notes that the forecast has not been audited, and explains reasons for performance changes. The document explicitly states that the final detailed financial data will be in the 2014 annual report. The document length is short (987 characters) and it is a forward-looking earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not the full annual report. Therefore, the correct classification is ER with high confidence. FY 2014
2015-01-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.